Insider Selling: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Director Sells $751,200.00 in Stock

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Director Michael Sinclair sold 60,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $12.52, for a total transaction of $751,200.00.

OPNT opened at $15.90 on Thursday. The company has a 50-day moving average of $13.97 and a 200-day moving average of $13.07. The company has a market capitalization of $63.99 million, a P/E ratio of -2.24 and a beta of 0.32. Opiant Pharmaceuticals Inc has a 1-year low of $9.98 and a 1-year high of $23.33.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.86. The company had revenue of $6.78 million during the quarter, compared to the consensus estimate of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. As a group, sell-side analysts expect that Opiant Pharmaceuticals Inc will post 1.05 earnings per share for the current year.



Several institutional investors and hedge funds have recently added to or reduced their stakes in OPNT. Stonepine Capital Management LLC boosted its holdings in shares of Opiant Pharmaceuticals by 7.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock valued at $4,180,000 after buying an additional 20,574 shares during the period. Granite Investment Partners LLC acquired a new position in shares of Opiant Pharmaceuticals in the 1st quarter valued at about $356,000. Morgan Stanley boosted its holdings in shares of Opiant Pharmaceuticals by 1,000.3% in the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock valued at $297,000 after buying an additional 20,377 shares during the period. BlackRock Inc. boosted its holdings in shares of Opiant Pharmaceuticals by 93.5% in the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock valued at $276,000 after buying an additional 10,045 shares during the period. Finally, Spark Investment Management LLC boosted its holdings in shares of Opiant Pharmaceuticals by 17.6% in the 1st quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after buying an additional 2,265 shares during the period. 20.81% of the stock is owned by institutional investors.

Several research firms have recently weighed in on OPNT. Northland Securities reissued a “buy” rating on shares of Opiant Pharmaceuticals in a research report on Friday, August 2nd. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 6th. Finally, TheStreet raised shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Friday, August 30th.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.